STOCKHOLM, May 16, 2019 /PRNewswire/ --
Alligator Bioscience (Nasdaq Stockholm: ATORX) ,
today announces that the outline of the ongoing Phase I study with
the bispecific drug candidate ATOR-1015 will be showcased at the
American Society of Clinical Oncology (ASCO) Annual Meeting held in
Chicago on May 31- June 4, 2019.
The ATOR-1015 Phase I study is a first-in-human dose-escalation
study in patients with advanced solid malignancies (NCT03782467).
The primary aim of the study is to investigate the safety and
tolerability of ATOR-1015 and to identify the maximum tolerated
dose/recommended dose for subsequent Phase II studies. The first
patient was dosed in March 2019 and
the study results are expected to read out in the second half of
2020.
The study design includes accelerated dose titration with one
patient cohorts, followed by a modified 3+3 design with at least
three patients per dose level. At the maximum tolerated dose, or at
a lower dose level, an expansion cohort is planned with up to 14
patients, for additional safety and efficacy evaluation.
Charlotte Russell, Chief Medical
Officer at Alligator Bioscience will present the poster (#292b)
entitled "A first-in-human, multicenter, open-label, phase I
study in patients with advanced and/or refractory solid
malignancies to evaluate the safety of intravenously administered
ATOR-1015" by Jeffrey Yachnin et
al. on June 1 from 8-11 a.m. CDT in the session Developmental
Immunotherapy and Tumor Immunobiology.
"While immune activation through CTLA-4 has shown impressive
efficacy in multiple cancers, it is coupled with severe toxicity.
We believe that ATOR-1015 will be at least as effective as the
approved monospecific CTLA-4 antibody and with less side effects,"
said Per Norlén, CEO of Alligator Bioscience.
For further information, please contact:
Cecilia Hofvander,
Director IR & Communications
Phone +46-46-540-82-06
E-mail: cecilia.hofvander@alligatorbioscience.com
This information was submitted for publication, through the
agency of the contact person set out above, at 08:30 a.m. CEST (2:30 a.m.
EDT) on May 16, 2019.
About ATOR-1015
ATOR-1015 is a next generation CTLA-4 bispecific antibody
developed for tumor-directed immunotherapy with increased
capability of regulatory T cell depletion. It is wholly owned by
Alligator. ATOR-1015 binds to two different immune receptors: the
checkpoint receptor CTLA-4 and the co-stimulatory receptor OX40.
The immune activation is increased in areas where both target
molecules are expressed at high levels, notably in the tumor
microenvironment, which is believed to reduce adverse immune
reactions.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology
company developing tumor-directed immuno-oncology antibody drugs.
Alligator's growing pipeline includes five lead clinical and
preclinical drug candidates: ADC-1013, ATOR-1015, ATOR-1017,
ALG.APV-527 and ATOR-1144. Alligator's shares are listed on Nasdaq
Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55
employees. For more information, please visit
www.alligatorbioscience.com.
ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc. for
global development and commercialization.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-to-present-the-ator-1015-phase-i-study-outline-at-asco,c2814798
The following files are available for download:
https://mb.cision.com/Main/12681/2814798/1045947.pdf
|
Alligator Bioscience
to present the ATOR-1015 Phase I study outline at ASCO
|
View original
content:http://www.prnewswire.com/news-releases/alligator-bioscience-to-present-the-ator-1015-phase-i-study-outline-at-asco-300851460.html
SOURCE Alligator Bioscience